Piperine and Drug Interactions: The Other Side of Bioavailability

Read the label on a piperine supplement and it will tell you, accurately, that piperine helps your body absorb more of what you take with it. That sentence is the product's entire reason to exist. Now read it again as a pharmacist would:

A supplement sold specifically to make other substances absorb better will do exactly that to your prescription medicines too — and nobody adjusts the dose for it.

That is the whole of this page in one line. It is not a hypothetical concern and it is not the usual vague herbal hand-waving about "possible interactions." Piperine's interaction potential rests on the same body of evidence as its marketed benefit: human pharmacokinetic studies in which piperine measurably raised the blood levels of named prescription drugs, some of them in patients already stabilised on treatment. The mechanism does not know the difference between the curcumin you wanted more of and the tacrolimus keeping your transplanted kidney alive.

This is the most clinically important page in the Long Pepper set. If you take any regular medication, it is the one to read.

Table of Contents

1. One Mechanism, Two Names
2. Why CYP3A4 Inhibition Is Such a Wide Net
3. Narrow Therapeutic Index: The Idea That Matters Most
4. Documented Human Interactions
5. Drug Classes Where This Matters
6. The Grapefruit Comparison, and Where It Breaks Down
7. Hidden Exposure: You May Already Be Taking Piperine
8. Interactions Are Not Always in the Direction You Expect
9. Does Separating Doses Help?
10. What to Actually Do
11. How to Raise It With a Prescriber
12. Evidence Tiers
13. Key Research Papers
14. Connections

One Mechanism, Two Names

The bioavailability page works through the mechanism in detail. The short version, because you need it in hand:

• Piperine inhibits CYP3A4, the enzyme in your gut wall and liver that chemically dismantles a large share of oral drugs before they reach your bloodstream.
• Piperine inhibits P-glycoprotein, the pump in your intestinal lining that ejects absorbed molecules back into the gut.
• Piperine slows glucuronidation, the conjugation step that tags molecules for excretion.

Slow all three and more of a swallowed dose reaches the blood. Marketed as a benefit, that is called bioenhancement. Recorded in a medical chart, the identical event is called a pharmacokinetic drug interaction. There is no difference in the underlying biology — only in whether the increase was intended and whether anyone accounted for it.

The uncomfortable implication: the better a bioenhancer works, the more dangerous it is next to a medication list. A piperine product that failed to raise blood levels would be useless and safe. One that works as advertised is, by definition, capable of raising a drug level by a clinically meaningful amount.

Why CYP3A4 Inhibition Is Such a Wide Net

Most drug interactions are narrow: one drug, one enzyme, one other drug. CYP3A4 is the exception, and the reason is arithmetic.

CYP3A4 is the most abundant cytochrome P450 in the human liver and the dominant one in the intestinal wall. It is also remarkably promiscuous — it accepts a very wide range of molecular shapes as substrates. Pharmacology reviews commonly estimate that CYP3A4 participates in the metabolism of something on the order of half of all drugs in clinical use. P-glycoprotein handles a large, overlapping set. When a single compound inhibits both, the population of potentially affected medicines is not a list you can memorise. It is a majority of the pharmacy.

There is one genuinely reassuring nuance, and it deserves stating because it is easy to over-alarm here. Volak and colleagues, in Drug Metabolism and Disposition in 2008, compared piperine and curcuminoids against a panel of human enzymes and found piperine to be a relatively selective CYP3A4 inhibitor rather than a broad P450 shutdown — and found the curcuminoids themselves to be the broader inhibitors of the pair. So piperine's footprint is CYP3A4 plus P-gp plus glucuronidation, not "all of drug metabolism." That is still an enormous footprint, but it is a defined one. Tier: preclinical, human recombinant enzymes.

The other nuance runs the wrong way. Piperine's effect is not purely a gut-lumen phenomenon. Because it also inhibits hepatic CYP3A4, the interaction is not confined to whatever happens to be in your intestine at the same moment as the capsule. This matters for the timing question below.

Narrow Therapeutic Index: The Idea That Matters Most

If you take one concept away from this page, take this one, because it tells you whether to worry.

Every drug has a range of blood concentrations in which it works, and above which it harms you. For most medicines that gap is generously wide. Take a little too much paracetamol at a normal dose and nothing happens; take slightly more amoxicillin than intended and the consequence is nil. These are wide therapeutic index drugs, and a 30% rise in blood level is unlikely to matter.

Some drugs have almost no gap. The concentration that treats you and the concentration that hurts you are close together, which is precisely why these drugs are dose-titrated over weeks, monitored with blood tests, and why your prescriber fusses about brand switches. These are narrow therapeutic index (NTI) drugs. For an NTI drug, a 30% rise in blood level is not a rounding error — it can be the difference between a therapeutic level and a toxic one.

The rule that follows is simple and it is the practical core of this page:

1. If you take a narrow-therapeutic-index medication, do not start a piperine supplement without talking to your prescriber. Not "probably fine," not "it's natural" — ask first.
2. If you are unsure whether your medication is narrow-index, that is itself a reason to ask. A pharmacist can answer this in thirty seconds and it is exactly the kind of question they want.
3. Signals that you are probably on an NTI drug: you get regular blood tests to check the drug level itself; your dose was adjusted several times before it settled; you were warned to keep to one manufacturer; the dose is written in odd fractions; or you were told which foods to avoid.

Documented Human Interactions

These are the interactions with actual human pharmacokinetic data behind them. All were done with isolated piperine, and most of the underlying chemistry work is black-pepper research — see the borrowed-evidence discussion on the bioavailability page. Piperine is one molecule regardless of which Piper species it came from, so the findings transfer; the dose delivered by a given amount of long pepper does not.

• Phenytoin (antiepileptic, classically narrow-index). Raised plasma levels have been reported both in healthy volunteers and — more tellingly — by Pattanaik and colleagues in Phytotherapy Research in 2006 in patients with epilepsy already at steady state on the drug. Velpandian and colleagues had earlier reported interference with phenytoin pharmacokinetics from piperine in food, in the European Journal of Drug Metabolism and Pharmacokinetics in 2001. Tier: small human studies, including in patients. This is the interaction with the clearest patient-level evidence, and phenytoin is a drug where toxicity means ataxia, nystagmus and confusion.
• Carbamazepine (antiepileptic). The same group reported a pharmacokinetic interaction between single-dose piperine and steady-state carbamazepine in epilepsy patients, in Phytotherapy Research in 2009. Tier: small human study in patients.
• Propranolol and theophylline. Bano and colleagues reported increased bioavailability of both in healthy volunteers given piperine, in the European Journal of Clinical Pharmacology in 1991. Theophylline is a textbook narrow-index drug — toxicity presents as nausea, tachycardia, tremor and seizures. Tier: small human PK study.
• Rifampicin (antituberculous). Here the interaction has been pursued deliberately as a therapeutic strategy: Indian researchers reported raised rifampicin blood levels with piperine in pulmonary tuberculosis patients in the 1980s, and a piperine-containing rifampicin formulation was subsequently developed on that basis to achieve therapeutic levels from a lower drug dose. Tier: small human studies plus a formulation programme. This is the clearest proof that the effect is real enough to build a product around — and therefore real enough to matter when it is unintended.
• Nevirapine (antiretroviral). A randomised, placebo-controlled crossover study reported altered nevirapine pharmacokinetics with piperine under fasting conditions. Tier: small human crossover. Antiretroviral regimens depend on maintaining levels within a window; drifting outside it risks toxicity in one direction and resistance in the other.
• Curcumin (not a drug, but the same event). The Shoba 1998 Planta Medica study — about a twenty-fold rise in curcumin bioavailability from 20 mg of piperine. Tier: small human PK study. Included here because it is the magnitude reference point: the mechanism is capable of very large multiples when the substrate is heavily first-pass metabolised.

What this list is not. It is not a complete interaction inventory, and treating it as one would be the most dangerous possible misreading. Only a handful of drugs have ever been formally studied with piperine, because such studies are expensive and nobody funds interaction trials for a supplement ingredient. The absence of a drug from this list means nobody looked, not that it is safe. The reasoning that should drive your caution is mechanistic: if your drug is a CYP3A4 or P-gp substrate with a narrow window, assume the interaction is plausible.

Drug Classes Where This Matters

Because a complete list is impossible, what follows is representative classes, chosen because they are common, because their members are known CYP3A4 or P-glycoprotein substrates, and because a modest rise in level does real harm. This is a prompt for a conversation with your pharmacist, not a substitute for one.

1. Immunosuppressants — ciclosporin, tacrolimus, sirolimus. The highest-stakes group on the page. All are narrow-index CYP3A4 and P-gp substrates, all are monitored by blood level, and the consequences of getting the level wrong are graft rejection on one side and kidney toxicity and infection on the other. Transplant recipients are routinely counselled about grapefruit for exactly this reason. Treat piperine the same way.
2. Many statins — particularly simvastatin, lovastatin and atorvastatin. These are CYP3A4 substrates, and raised levels increase the risk of muscle injury, from aching muscles up to rhabdomyolysis. Note that not all statins behave the same way here; pravastatin and rosuvastatin are handled differently, which is precisely the kind of distinction worth asking a pharmacist about rather than guessing.
3. Certain calcium-channel blockers — notably the dihydropyridines such as nifedipine, felodipine and amlodipine, plus verapamil and diltiazem. CYP3A4 substrates with dose-dependent effects on blood pressure and heart rate. Raised levels can mean dizziness, flushing, oedema and hypotension.
4. Some benzodiazepines and other CNS drugs — midazolam, triazolam, alprazolam, along with various Z-drugs and several antipsychotics and antidepressants. Midazolam is so reliably a CYP3A4 substrate that pharmacologists use it as the probe drug for measuring CYP3A4 activity. The clinical consequence of raised levels is excess sedation and impaired coordination — a falls risk in older people.
5. Antiepileptics — phenytoin and carbamazepine have direct human data, as above. Their toxicity is neurological and easy to mistake for something else.
6. Digoxin. The classic P-glycoprotein substrate with a famously tiny margin. Digoxin toxicity is nausea, visual disturbance and dangerous arrhythmias.
7. Direct oral anticoagulants — rivaroxaban, apixaban, dabigatran, edoxaban. CYP3A4 and/or P-gp substrates, and unlike warfarin there is no routine blood test that would catch a drift upward. Raised levels mean bleeding.
8. Some antiretrovirals and antifungals. Many protease inhibitors, non-nucleoside reverse transcriptase inhibitors and azole antifungals are CYP3A4 substrates, inhibitors, or both — these drug classes are already a dense thicket of interactions before anything is added, and nevirapine has direct piperine data.
9. Oral cancer drugs and targeted therapies. A large share of tyrosine kinase inhibitors are CYP3A4 and P-gp substrates with narrow windows and severe toxicity profiles. Do not add piperine, Trikatu or a piperine-containing turmeric supplement during cancer treatment without asking the oncology team. Oncology pharmacists expect this question and will not judge you for asking it.
10. Thyroid replacement, and in general anything you were titrated onto slowly. If it took months of blood tests to find your dose, that dose was found in the absence of a bioenhancer. Adding one changes the conditions the titration was performed under.
11. Anything with a narrow therapeutic index, full stop — including drugs not named above. This catch-all is doing more work than the specific entries.

Directionally the concern is almost always "too much drug," not "too little." That is worth knowing because too-much-drug does not look like a treatment failure. It looks like new symptoms, and new symptoms get attributed to almost anything before somebody thinks of the capsule you did not mention.

The Grapefruit Comparison, and Where It Breaks Down

Grapefruit is the interaction everyone has heard of, and it is the right analogy to start from. Grapefruit's furanocoumarins inhibit intestinal CYP3A4, which is why dozens of drug leaflets carry a grapefruit warning and why transplant clinics hand out written advice about it. Bailey and colleagues laid out the clinical scope of it in the Canadian Medical Association Journal in 2013 under the title "Grapefruit-medication interactions: forbidden fruit or avoidable consequences?" — a good read if you want to see how seriously mainstream medicine takes a dietary CYP3A4 inhibitor. Tier: review of documented human interactions. The grapefruit page covers this in more depth.

Piperine works on the same machinery, and adds P-gp inhibition and reduced glucuronidation on top. So far, so analogous. Four differences make piperine the more insidious of the two, and none of them are in piperine's favour:

1. Nobody warns you about it. Grapefruit has been on drug leaflets for thirty years. Piperine appears on supplement labels as a selling point, in text designed to reassure rather than caution.
2. Grapefruit is food you notice eating. Piperine arrives in a capsule you may have chosen for something else entirely — a turmeric supplement, a "metabolism" blend, a multivitamin with an absorption complex.
3. Grapefruit inhibition is largely intestinal. Piperine also inhibits hepatic CYP3A4, so the effect is less avoidable by separating doses in time.
4. Grapefruit is not sold on the strength of the interaction. Piperine is. Its dose was chosen to maximise the very effect that constitutes the hazard.

If your medication leaflet says "avoid grapefruit," treat that as a strong signal that it is a CYP3A4 substrate — and therefore that a piperine supplement deserves the same conversation. That single heuristic is the most useful thing on this page for a reader who does not want to learn any pharmacology.

Hidden Exposure: You May Already Be Taking Piperine

People assess supplement risk by looking at bottles they think of as drugs. Piperine slips through because it is usually an ingredient rather than a product.

Places piperine turns up without being the headline:

• Turmeric and curcumin supplements. The most common route by a wide margin. Piperine is added specifically to fix curcumin's absorption problem, frequently as a branded black-pepper extract standardised to around 95% piperine. Check the "other ingredients" line, not just the front of the label.
• Trikatu. The classic Ayurvedic three-pungents formula — long pepper, black pepper and dried ginger. It concentrates piperine from two Piper species at once, and it is added to a great many compound Ayurvedic formulas precisely because of the bioenhancement effect. See the Trikatu and safety page.
• Multi-ingredient "absorption" or "bioavailability" complexes in protein powders, greens blends, joint formulas, sports supplements and multivitamins.
• Thermogenic and weight-loss blends, where piperine is included for a claimed metabolic effect as well as for absorption.
• Ayurvedic compound preparations generally. If a formula lists pippali, maricha or Trikatu among its ingredients, piperine is in there.

Practical step: read every supplement label you take for the words piperine, black pepper extract, Piper nigrum, Piper longum, pippali, maricha, Trikatu, or a branded pepper-extract trade name. Then add up the milligrams across products — two supplements each contributing 10 mg is a 20 mg daily exposure, the same figure used in the curcumin study.

Interactions Are Not Always in the Direction You Expect

Two complications, both of which argue for asking a professional rather than reasoning it out yourself.

Prodrugs run backwards. Some medicines are inactive as swallowed and are converted into their active form by the very enzymes piperine inhibits. Inhibit the enzyme and you get less active drug, not more — the interaction shows up as loss of effect rather than as toxicity. Clopidogrel is the best-known example of enzyme-dependent activation in this general family. A reader who has internalised "piperine raises drug levels" will not see this coming, which is exactly why "check with a pharmacist" beats a rule of thumb.

Enzyme systems adapt over time. Short-term inhibition and long-term daily exposure are not always the same thing; some plant constituents inhibit acutely and induce enzyme expression over weeks. The human data on piperine are almost entirely single-dose or short-course, so what daily piperine does to CYP3A4 activity over months is simply not well characterised. That is an honest gap, not a reassurance.

And curcumin is not innocent either. The Volak 2008 work found curcuminoids inhibiting a broader spread of P450, UGT and sulfotransferase enzymes than piperine did. A curcumin-plus-piperine supplement therefore presents two interaction profiles, not one, and the interaction risk of the combination cannot be pinned entirely on the pepper.

Does Separating Doses Help?

The intuitive fix is to take the supplement at a different time of day from the medication. It is a reasonable precaution and it is not a solution.

What separation achieves: it reduces simultaneous presence in the intestinal lumen, which lowers the peak local concentration of piperine at the gut wall while your drug is being absorbed. For a drug whose interaction is dominated by intestinal CYP3A4 and P-gp, that genuinely helps.

What it does not achieve: piperine also inhibits hepatic CYP3A4. Liver enzyme inhibition does not switch off the moment the capsule leaves your stomach, and the drug in your bloodstream keeps passing through the liver all day. Separation attenuates the interaction; it does not abolish it.

The honest position: for a wide-therapeutic-index medication, separating doses by several hours is a sensible belt-and-braces measure and probably sufficient. For a narrow-index drug, separation is not an adequate substitute for a conversation with your prescriber, and it is certainly not a reason to skip that conversation. There is no published dosing-interval study that establishes a safe gap, so anyone who gives you a specific number of hours is guessing.

What to Actually Do

1. Cook with long pepper freely. Culinary use of the spice — a grated spike over a dish, a whole spike in a braise — is a small, food-diluted exposure. Human populations have eaten Piper spices daily for millennia. This page is not about your pepper mill.
2. Inventory your labels. Find every product you take that contains piperine, black pepper extract, Piper anything, pippali, maricha or Trikatu. Add up the daily milligrams.
3. Check your medication list against the classes above, and against the grapefruit heuristic: if a leaflet warns about grapefruit, the drug is very likely a CYP3A4 substrate.
4. If anything matches, ask before you continue. A community pharmacist can answer this at the counter, free, without an appointment. It is one of the things they are best at.
5. If you are on an immunosuppressant, an anticoagulant, digoxin, an antiepileptic, or oral cancer therapy, ask first and do not self-clear. These are the groups where the downside is severe rather than merely inconvenient.
6. Do not stop a prescribed medication because of anything on this page. The fix for a supplement interaction is to reconsider the supplement, never to alter the prescription on your own.
7. Stop piperine supplements well before planned surgery — a fortnight is the conventional margin for supplements of this kind — and tell the surgical and anaesthetic team what you were taking. Anaesthetic agents include CYP3A4 substrates, and high-dose piperine has shown antiplatelet activity in laboratory work.
8. If you start a piperine supplement and feel unexpectedly different within days — unusually drowsy, dizzy, nauseated, bruising more easily, aching muscles — consider the interaction, stop the supplement, and get advice.

How to Raise It With a Prescriber

The most common failure is not a bad answer; it is that the question never gets asked, because "it's just a herbal supplement" does not feel like a medical disclosure. Two lines fix that.

Say: "I'm taking a supplement that contains piperine — black pepper extract — at X milligrams a day. I understand it inhibits CYP3A4 and P-glycoprotein. Does that matter for any of my medications?"

That sentence does three useful things. It names the compound rather than the brand. It gives a number rather than "a bit." And it names the mechanism, which lets a clinician answer immediately instead of having to look up an unfamiliar botanical.

Bring the actual bottle if you can, because the informative part is usually the small print. And if the honest answer to "how much piperine?" is "I don't know, it's in a proprietary blend," say that too — an undisclosed quantity of a CYP3A4 inhibitor is itself a reason for caution, and it is a fair reason to prefer a product that states its dose.

Evidence Tiers

• Piperine inhibits human CYP3A4, P-glycoprotein and intestinal glucuronidation — preclinical, on human proteins, replicated. Mechanistically about as secure as this kind of claim gets.
• Piperine raises blood levels of phenytoin, carbamazepine, propranolol, theophylline, rifampicin and nevirapine in humans — multiple small human pharmacokinetic studies, several in patients rather than volunteers. Small samples; consistent direction.
• The named drug classes above are affected — mechanistic inference from known CYP3A4 and P-gp substrate status, not from piperine-specific trials. Strong reasoning, absent direct data.
• Clinically significant harm has occurred in patients from piperine supplements — not established. There is no large case series, largely because supplement use is under-reported and interactions of this kind are rarely attributed. Absence of documented harm here reflects absence of surveillance, not demonstrated safety.
• A specific safe dose-separation interval exists — not established. No study defines one.
• Culinary spice use poses interaction risk — no evidence that it does, and long dietary history against it.
• Long pepper specifically (rather than isolated piperine) causes these interactions at traditional doses — not directly studied. The borrowed-evidence problem applies: piperine is piperine, but delivered dose per gram of spice is not established. Trikatu, which concentrates two piperine sources, is the realistic worry.

Key Research Papers

Each entry links a live PubMed topic search rather than a fixed record.

1. Bhardwaj RK, Glaeser H, Becquemont L, et al. "Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4." The Journal of Pharmacology and Experimental Therapeutics, 2002. The paper that made the interaction predictable rather than speculative. Preclinical, human proteins. — PubMed search
2. Pattanaik S, Hota D, Prabhakar S, et al. "Effect of piperine on the steady-state pharmacokinetics of phenytoin in patients with epilepsy." Phytotherapy Research, 2006. Notable because the subjects were patients on established treatment, not volunteers. Small human study in patients. — PubMed search
3. Pattanaik S, Hota D, Prabhakar S, et al. "Pharmacokinetic interaction of single dose of piperine with steady-state carbamazepine in epilepsy patients." Phytotherapy Research, 2009. A second antiepileptic, same direction. Small human study in patients. — PubMed search
4. Bano G, Raina RK, Zutshi U, et al. "Effect of piperine on bioavailability and pharmacokinetics of propranolol and theophylline in healthy volunteers." European Journal of Clinical Pharmacology, 1991. Two more prescription drugs, one of them narrow-index. Small human PK study. — PubMed search
5. Velpandian T, Jasuja R, Bhardwaj RK, et al. "Piperine in food: interference in the pharmacokinetics of phenytoin." European Journal of Drug Metabolism and Pharmacokinetics, 2001. Frames dietary piperine as a pharmacokinetic variable. Preclinical and human PK. — PubMed search
6. Volak LP, Ghirmai S, Cashman JR, Court MH. "Curcuminoids inhibit multiple human cytochromes P450, UDP-glucuronosyltransferase, and sulfotransferase enzymes, whereas piperine is a relatively selective CYP3A4 inhibitor." Drug Metabolism and Disposition, 2008. Defines piperine's footprint and shows curcumin carries its own. Preclinical, human enzymes. — PubMed search
7. Zhou S, Lim LY, Chowbay B. "Herbal modulation of P-glycoprotein." Drug Metabolism Reviews, 2004. Context for why efflux-pump inhibition is a general herb-drug problem. Review. — PubMed search
8. Hu Z, Yang X, Ho PC, et al. "Herb-drug interactions: a literature review." Drugs, 2005. Places piperine among the plant constituents clinicians are told to ask about. Review. — PubMed search
9. Bailey DG, Dresser G, Arnold JM. "Grapefruit-medication interactions: forbidden fruit or avoidable consequences?" Canadian Medical Association Journal, 2013. The reference point for how seriously a dietary CYP3A4 inhibitor is taken in mainstream practice. Review of human interactions. — PubMed search
10. Han HK. "The effects of black pepper on the intestinal absorption and hepatic metabolism of drugs." Expert Opinion on Drug Metabolism & Toxicology, 2011. A compact review written from the drug-metabolism side rather than the supplement side. Review. — PubMed search
11. Shoba G, Joy D, Joseph T, et al. "Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers." Planta Medica, 1998. Included here for magnitude: the mechanism can produce very large multiples. Small human PK study. — PubMed search
12. Kasibhatta R, Naidu MU. "Influence of piperine on the pharmacokinetics of nevirapine under fasting conditions: a randomised, crossover, placebo-controlled study." Drugs in R&D, 2007. An antiretroviral, in a controlled crossover design. Small randomised human crossover. — PubMed search

Live PubMed Topic Searches

1. Piperine drug-interaction pharmacokinetics
2. Narrow therapeutic index drugs and CYP3A4 interactions
3. Piperine with tacrolimus and ciclosporin
4. Bioenhancer supplements and interaction risk
5. P-glycoprotein inhibition and digoxin
6. Under-reporting of supplement use to prescribers
7. Piperine and rifampicin in tuberculosis
8. Curcumin supplements and anticoagulant interactions

External Resources

• National Center for Complementary and Integrative Health — plain-language US government summaries, including on telling your clinicians what you take.
• DailyMed — the US National Library of Medicine's index of official drug labelling; the place to check whether your medication is a CYP3A4 substrate or carries a grapefruit warning.
• PubMed — the literature index behind every citation above.

Connections

• All Herbs
• Long Pepper, Piperine and the Bioavailability Question — the same mechanism read as a benefit. The two pages are one story.
• Long Pepper — the main article, including the full cautions list.
• Species, Trikatu and Safety — Trikatu concentrates piperine from two species, which is the realistic exposure route.
• Digestive and Respiratory Uses — the traditional indications and how strong that evidence actually is.
• Grapefruit — the dietary CYP3A4 inhibitor everyone has been warned about, and the best analogy for this page.
• Black Pepper: Sources and Safety — the other piperine source, with its own safety discussion.
• Black Pepper — Piper nigrum, where most of the primary interaction evidence was generated.
• Curcumin — carries its own enzyme-inhibition profile; a combination product has two interaction risks, not one.
• Turmeric: Bioavailability and Forms — absorption strategies that do not involve inhibiting your drug-metabolising enzymes.
• Turmeric: Liver Health — the organ doing most of the metabolism discussed here.
• Liver Function Tests — the standard panel for monitoring hepatic health alongside supplements.

Safety note and disclaimer. This page is educational and is not medical advice, and it is not a complete interaction list — no such list exists for piperine, because most of the relevant studies have never been done. If you take any prescription medication and are considering a piperine, Trikatu, black pepper extract or standardised long pepper supplement, ask your prescriber or pharmacist first, and show them the label with its milligram figure. Do not stop or change a prescribed medicine on the basis of anything written here. Culinary use of long pepper and black pepper as spices is a much smaller exposure and is not the subject of these cautions. Piperine supplements should be avoided in pregnancy and breastfeeding, and are not appropriate for children. Long pepper is not a treatment for any disease.

Back to Table of Contents